Signifikant færre Fablyn- behandlede kvinder fik moderate eller alvorlige rygsøjlefrakturer (bestemt ved Genant- skala) sammenlignet med placebobehandlede kvinder (5, 2% placebobehandlede kvinder versus 3, 3% Fablyn- behandlede kvinder; p = 0, 0006).
Significantly fewer women treated with FABLYN experienced moderate or severe vertebral fractures (as determined by the Genant scale) compared to women treated with placebo (5.2% placebo-treated women versus 3.3% FABLYN-treated women; p = 0.0006).